Outcomes in COVID-19 vitamin A studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 79% 0.21 [0.07-0.61] 4/120 20/120 79% improvement Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment -282% 3.83 [1.58-9.24] 9/10 4/17 -282% improvement Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% PEP 64% 0.36 [0.23-0.54] 20/97 65/112 64% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 55% 0.45 [0.18-1.10] 41/290 142/346 55% improvement 6 vitamin A COVID-19 studies c19early.com/va Sep 24, 2021 Tau​2 ​ = 0.97; I​2 ​ = 82.0%; Z = 1.75 Effect extraction pre-specified Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 67% 0.33 [0.07-1.57] 2/50 6/50 67% improvement Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% PEP 64% 0.36 [0.23-0.54] 20/97 65/112 64% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 66% 0.34 [0.24-0.48] 30/210 124/259 66% improvement 4 vitamin A COVID-19 studies after exclusions c19early.com/va Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 6.01 Effect extraction pre-specified Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] 2/70 14/70 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 86% 0.14 [0.03-0.61] 2/70 14/70 86% improvement Sarohan -282% 3.83 [1.58-9.24] 9/10 4/17 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment -282% 3.83 [1.58-9.24] 9/10 4/17 -282% improvement Tepasse 70% 0.30 [0.07-0.97] 4/29 5/11 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Sufficiency 70% 0.30 [0.07-0.97] 4/29 5/11 70% improvement All studies 42% 0.58 [0.07-4.59] 15/109 23/98 42% improvement 3 vitamin A COVID-19 mortality results c19early.com/va Sep 24, 2021 Tau​2 ​ = 2.99; I​2 ​ = 90.1%; Z = 0.52 Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tomasa-Irriguible 61% 0.39 [0.15-0.80] 6/34 54/86 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Sufficiency 61% 0.39 [0.15-0.80] 6/34 54/86 61% improvement All studies 61% 0.39 [0.18-0.81] 6/34 54/86 61% improvement 1 vitamin A COVID-19 ICU result c19early.com/va Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 2.50 Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 79% 0.21 [0.07-0.61] 4/120 20/120 79% improvement Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment -282% 3.83 [1.58-9.24] 9/10 4/17 -282% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 54% 0.46 [0.13-1.65] 21/193 77/234 54% improvement 5 vitamin A COVID-19 serious outcomes c19early.com/va Sep 24, 2021 Tau​2 ​ = 1.75; I​2 ​ = 84.1%; Z = 1.19 Effect extraction pre-specified Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 64% 0.36 [0.23-0.54] 20/97 65/112 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% PEP 64% 0.36 [0.23-0.54] 20/97 65/112 64% improvement All studies 64% 0.36 [0.23-0.54] 20/97 65/112 64% improvement 1 vitamin A COVID-19 case result c19early.com/va Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 4.82 Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 86% 0.14 [0.03-0.61] 2/70 14/70 86% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 75% 0.25 [0.13-0.48] 10/133 67/167 75% improvement 3 vitamin A COVID-19 peer reviewed trials c19early.com/va Sep 24, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 4.17 Effect extraction pre-specified Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Tomasa-Irriguible 61% 0.39 [0.15-0.80] ICU 6/34 54/86 Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tepasse 45% 0.55 [0.16-1.00] progression 13/29 9/11 vitamin A COVID-19 outcomes c19early.com/va Sep 24, 2021 Favors vitamin A Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
